Logo image of ACLX

ARCELLX INC (ACLX) Stock Fundamental Analysis

NASDAQ:ACLX - Nasdaq - US03940C1009 - Common Stock - Currency: USD

62.02  +1.33 (+2.19%)

Premarket: 62.01 -0.01 (-0.02%)

Fundamental Rating

3

ACLX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACLX as it has an excellent financial health rating, but there are worries on the profitability. ACLX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ACLX had negative earnings in the past year.
In the past year ACLX has reported a negative cash flow from operations.
ACLX had negative earnings in each of the past 5 years.
In the past 5 years ACLX reported 4 times negative operating cash flow.
ACLX Yearly Net Income VS EBIT VS OCF VS FCFACLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of ACLX (-15.09%) is better than 82.92% of its industry peers.
ACLX has a Return On Equity of -23.60%. This is amongst the best in the industry. ACLX outperforms 84.15% of its industry peers.
Industry RankSector Rank
ROA -15.09%
ROE -23.6%
ROIC N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ACLX Yearly ROA, ROE, ROICACLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACLX Yearly Profit, Operating, Gross MarginsACLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

7

2. Health

2.1 Basic Checks

ACLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACLX has been increased compared to 1 year ago.
The number of shares outstanding for ACLX has been increased compared to 5 years ago.
ACLX has a better debt/assets ratio than last year.
ACLX Yearly Shares OutstandingACLX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ACLX Yearly Total Debt VS Total AssetsACLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 7.30 indicates that ACLX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.30, ACLX belongs to the top of the industry, outperforming 86.44% of the companies in the same industry.
There is no outstanding debt for ACLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.3
ROIC/WACCN/A
WACC10.19%
ACLX Yearly LT Debt VS Equity VS FCFACLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ACLX has a Current Ratio of 4.78. This indicates that ACLX is financially healthy and has no problem in meeting its short term obligations.
ACLX has a Current ratio (4.78) which is comparable to the rest of the industry.
A Quick Ratio of 4.78 indicates that ACLX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.78, ACLX is in line with its industry, outperforming 54.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.78
Quick Ratio 4.78
ACLX Yearly Current Assets VS Current LiabilitesACLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

ACLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.05%.
ACLX shows a decrease in Revenue. In the last year, the revenue decreased by -2.16%.
EPS 1Y (TTM)-36.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.14%
Revenue 1Y (TTM)-2.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.83%

3.2 Future

Based on estimates for the next years, ACLX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.59% on average per year.
Based on estimates for the next years, ACLX will show a very strong growth in Revenue. The Revenue will grow by 42.16% on average per year.
EPS Next Y-55.6%
EPS Next 2Y-27.09%
EPS Next 3Y-12.84%
EPS Next 5Y26.59%
Revenue Next Year-25.46%
Revenue Next 2Y20.93%
Revenue Next 3Y26.56%
Revenue Next 5Y42.16%

3.3 Evolution

ACLX Yearly Revenue VS EstimatesACLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
ACLX Yearly EPS VS EstimatesACLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACLX. In the last year negative earnings were reported.
Also next year ACLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACLX Price Earnings VS Forward Price EarningsACLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACLX Per share dataACLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as ACLX's earnings are expected to decrease with -12.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.09%
EPS Next 3Y-12.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCELLX INC

NASDAQ:ACLX (4/17/2025, 8:00:43 PM)

Premarket: 62.01 -0.01 (-0.02%)

62.02

+1.33 (+2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners102.94%
Inst Owner Change1.85%
Ins Owners0.69%
Ins Owner Change4.37%
Market Cap3.41B
Analysts85.6
Price Target117.87 (90.05%)
Short Float %14.32%
Short Ratio10.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.66%
Min EPS beat(2)-51.89%
Max EPS beat(2)-9.44%
EPS beat(4)2
Avg EPS beat(4)4.17%
Min EPS beat(4)-51.89%
Max EPS beat(4)72.99%
EPS beat(8)3
Avg EPS beat(8)-6.51%
EPS beat(12)4
Avg EPS beat(12)-25.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-34.09%
Min Revenue beat(2)-42.43%
Max Revenue beat(2)-25.74%
Revenue beat(4)2
Avg Revenue beat(4)10.35%
Min Revenue beat(4)-42.43%
Max Revenue beat(4)86.18%
Revenue beat(8)3
Avg Revenue beat(8)22.51%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.7%
PT rev (3m)-0.7%
EPS NQ rev (1m)2.11%
EPS NQ rev (3m)-12.85%
EPS NY rev (1m)-33.75%
EPS NY rev (3m)-32.59%
Revenue NQ rev (1m)0.94%
Revenue NQ rev (3m)-5.63%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-23.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.57
P/FCF N/A
P/OCF N/A
P/B 7.49
P/tB 7.49
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)-3.11
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS1.96
BVpS8.28
TBVpS8.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.09%
ROE -23.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 258.94%
Cap/Sales 12.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.78
Quick Ratio 4.78
Altman-Z 7.3
F-Score3
WACC10.19%
ROIC/WACCN/A
Cap/Depr(3y)494.02%
Cap/Depr(5y)435.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.14%
EPS Next Y-55.6%
EPS Next 2Y-27.09%
EPS Next 3Y-12.84%
EPS Next 5Y26.59%
Revenue 1Y (TTM)-2.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.83%
Revenue Next Year-25.46%
Revenue Next 2Y20.93%
Revenue Next 3Y26.56%
Revenue Next 5Y42.16%
EBIT growth 1Y-53.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-64.69%
EBIT Next 3Y3.94%
EBIT Next 5Y33.74%
FCF growth 1Y-152.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.21%
OCF growth 3YN/A
OCF growth 5YN/A